Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$30.59M+6.50%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen D. Griffin
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 235
- Beta
- 0.20
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.59
Financials
Revenue
$30.59M+6.5%Net Income
$-311.0K-103.8%EBITDA
$1.58M-88.5%Free Cash Flow
$6.72M+51.3%EPS (diluted)
$-0.02-103.7%Shares Outstanding (diluted)
13.39M-10.6%Operating Expenses
$19.55MCash & Debt
$44.96MReturn of Capital
$0.00Revenue by Segment (annual)
$64.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $112.82M | $-10.88M | $-0.76 |
| 2024 | $119.91M | $-56.38M | $-3.83 |
| 2023 | $120.79M | $-82.67M | $-5.64 |
| 2022 | $113.83M | $-14.86M | $-1.02 |
| 2021 | $147.79M | $4.13M | $0.29 |
| 2020 | $130.46M | $-23.98M | $-1.69 |
| 2019 | $114.61M | $27.19M | $1.93 |
| 2018 | $105.56M | $18.72M | $1.30 |
| 2017 | $113.42M | $31.82M | $2.18 |
| 2016 | $103.38M | $32.55M | $2.22 |
| 2015 | $93.00M | $30.76M | $2.06 |
| 2014 | $105.59M | $38.32M | $2.61 |
| 2013 | $75.08M | $20.57M | $1.46 |
| 2012 | $71.36M | $11.76M | $0.89 |
Valuation
ANIKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+114.29%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·16d ago·Positive
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Negative
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call Anika Therapeutics NASDAQ: ANIK reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts, even as it lowered its commercial channel growth outlook following slower U.S. elective surgery activity.
View source ↗ - Newszacks.com·16d ago·Positive
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates Anika Therapeutics (ANIK) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago.
View source ↗ - Newsglobenewswire.com·16d ago·Negative
…Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.
View source ↗ - Newszacks.com·88d ago·Positive
Best Momentum Stocks to Buy for August 26th BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
View source ↗ - Newszacks.com·90d ago·Negative
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
View source ↗ - Newszacks.com·93d ago·Positive
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why? ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
View source ↗ - Newszacks.com·95d ago·Positive
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
View source ↗ - Newszacks.com·100d ago·Neutral
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·104d ago·Positive
5 Stocks With Recent Price Strength to Tap August Rally Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.13 per share
Typical surprise +100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$0.29 vs $0.42miss
- Wed, Jul 29$0.42 vs $0.03beat
- Wed, Apr 29$0.27 vs $-0.07beat
- Thu, Feb 26$0.31 vs $-0.13beat
- Wed, Nov 5$0.04 vs $0.02beat
- Wed, Jul 30$-0.13 vs $-0.13beat
Estimates and results for ANIK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANIK officers and directors.
- Bought
- $264k
- Sold
- —
4 trades
0 trades
- Fischetti Gary Pbought
- Fischetti Gary Pbought
- Henneman John B Iiibought
- Griffin Stephen D.bought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (368d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (373d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
